Interestingly, when samples were analyzed separately based on tumor grade,HDAC11 expression levels correlated significantly with survival timeamong GL patients (p = 0.004, n = 15) but not among ODIII patients (p = 0.198, n= 20), suggesting that the decreased expression of HDAC11 in grade IVtumors (i.e. GL) may have a greater impact on tumor aggressiveness and clinicaloutcome than in the less aggressive grade III oligodendroglioma. Here, HDAC11 is linked to oligodendroglioma.